IP Library Patent Application 16656656
Patent Application
App. No. 16/656,656

DOSING REGIMEN FOR INJECTABLE CETIRIZINE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/656,656
Abstract

Described herein is a method of administering injectable cetirizine or levocetirizine including intravenously injecting a mammal in need thereof with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition, wherein the mammal receives a maximum daily dose of the cetirizine or levocetirizine that is no more than 15 times a maximum recommended daily clinical dose for the mammal.

Claims (13)

1 . A method of administering injectable cetirizine or levocetirizine to treat acute urticaria, comprising

intravenously injecting a human patient in an emergency department or clinic with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition,

determining, by the patient, a patient rated pruritus severity score at baseline and at a 1 hour assessment, and

a physician determining readiness to discharge as effective treatment of the acute urticaria based on the patient rated pruritus score reduction of at least 1 unit at the 1 hour assessment compared to the baseline assessment, wherein the human patient spends 1.7±0.9 hours in the emergency department or clinic.

2 . The method of claim 1 , wherein the therapeutically effective amount is the maximum recommended daily clinical dose.

3 . The method of claim 2 , wherein the maximum recommended human daily clinical dose is 2.5, 5 or 10 mg of cetirizine dihydrochloride administered once daily.

4 . The method of claim 3 , wherein the human subject is a child 6 months to 5 years and the maximum recommended human daily clinical dose of cetirizine dihydrochloride is 2.5 mg; the human subject is a child 6 to 11 years and the recommended human daily clinical dose of cetirizine dihydrochloride is 5 or 10 mg; or the human subject is an adult of adolescent 12 years or older and the maximum recommended daily clinical dose of cetirizine dihydrochloride is 10 mg.

5 . The method of claim 2 , wherein the maximum recommended human daily clinical dose is 1.25, 2.5 or 5 mg of levocetirizine dihydrochloride administered once daily.

6 . The method of claim 5 , wherein the human subject is a child 6 months 5 years and the recommended human daily clinical dose of levocetirizine dihydrochloride is 1.25 mg; the human subject is a child 6 to 11 years and the recommended human daily clinical dose of levocetirizine dihydrochloride is 2.5 or 5 mg; or the human subject is an adult of adolescent 12 years or older and the recommended daily clinical dose of levocetirizine dihydrochloride is 5 mg.

7 . The method of claim 1 , wherein the human patient returns to the emergency department or clinic.

8 . (canceled)

9 . The method of claim 1 , wherein the human subject has concomitant angioedema.

10 . The method of claim 1 , wherein the cetirizine dihydrochloride composition is a 10 mg/mL aqueous solution.

Assignments (5)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS AT R/F 63216/0020 Recorded May 13, 2026
From: ANTARES CAPITAL LP
To: JDP THERAPEUTICS LLC
Reel/Frame 075572/0854 →
RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED AT R/F 063227/0713 Recorded Jan 8, 2025
From: NEWSTONE CAPITAL PARTNERS, LLC
To: JDP THERAPEUTICS LLC
Reel/Frame 069840/0419 →
SECURITY INTEREST Recorded Apr 5, 2023
From: JDP THERAPEUTICS LLC
To: NEWSTONE CAPITAL PARTNERS, LLC
Reel/Frame 063227/0713 →
SECURITY INTEREST Recorded Apr 4, 2023
From: JDP THERAPEUTICS LLC
To: ANTARES CAPITAL LP, AS AGENT
Reel/Frame 063216/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2019
From: DU, JIE
To: JDP THERAPEUTICS LLC
Reel/Frame 050756/0965 →